{"filings":[{"id":528877,"accession_number":"0001193125-26-231040","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2026-05-19T21:01:02+00:00","items":["8.01"],"status":"ready","headline":"Cardiff Oncology sues Nerviano Medical Sciences over onvansertib license inventorship dispute","event_type":"litigation","confidence":"high","bullets":["Filed suit in SD California for injunctive relief and declaratory judgment it did not breach license agreement for onvansertib.","Dispute stems from NMS allegation that Cardiff failed to name an NMS employee as joint inventor on U.S. Patent Nos. 12,144,813 and 12,263,173.","Cardiff maintains no breach occurred; agreement does not require naming NMS employees on inventions made solely by Cardiff.","NMS sent written notice of alleged material breach on February 24, 2026, as previously disclosed.","Judicial intervention sought after prior discussions failed to resolve the disagreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":442876,"accession_number":"0001213037-26-000013","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2026-05-14T20:15:18+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cardiff Oncology reports Q1 cash $46.1M, FDA aligns on Phase 3 design for onvansertib","event_type":"earnings","confidence":"high","bullets":["Cash and investments $46.1M at Q1 end; net cash used $12.3M, runway into Q1 2027.","Completed End-of-Phase 2 FDA meeting; selected 30 mg onvansertib + FOLFIRI/bev for Phase 3.","Phase 2 CRDF-004: 30 mg arm ORR 72.2% vs SoC 43.2%; PFS HR 0.38 vs FOLFIRI/bev.","Appointed Mani Mohindru as permanent CEO, Josh Muntner as CFO, Ajay Aggarwal as COO.","Updated onvansertib data to be presented at ASCO 2026 rapid oral presentation."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":41000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91737,"accession_number":"0001193125-26-149623","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2026-04-09T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Cardiff Oncology appoints permanent CEO, new CFO and COO; Muntner gets stock option inducement","event_type":"leadership","confidence":"high","bullets":["Mani Mohindru promoted from interim to President & CEO; base salary $655K, $100K bonus plus 55% discretionary.","Josh Muntner named CFO effective April 6, 2026; base salary $475K, 40% bonus; granted options to buy 486,650 shares at $1.58.","Ajay Aggarwal appointed COO effective April 27, 2026; base salary $490K, 40% bonus; expects 400,000 stock options.","Muntner has 25+ years biopharma finance experience, previously CFO at Imvax and Mesoblast, raised over $300M combined.","Dr. Aggarwal brings 15+ years pharma experience, most recently SVP Clinical Development at Aclaris Therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91736,"accession_number":"0001193125-26-140152","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["1.01","5.02"],"status":"ready","headline":"Cardiff Oncology finalizes separation agreements with ex-CEO and ex-CFO","event_type":"leadership","confidence":"high","bullets":["Dr. Erlander to receive $635k salary over 12 months, $122k 2025 bonus, and 50% of 2026 target bonus pro-rated.","Mr. Levine to receive $490k salary over 12 months, $61.7k 2025 bonus, and 50% of 2026 target bonus pro-rated.","Erlander signs consulting agreement; stock options vest through June 2026, then exercisable for 12 months.","Levine's vested options exercisable for 12 months after separation date.","Erlander resigns from board of directors effective March 27, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102017,"accession_number":"0001193125-26-068668","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cardiff Oncology furnishes Feb 2026 corporate presentation; no material news","event_type":"other_material","confidence":"low","bullets":["Corporate slide presentation furnished as Exhibit 99.1 for investor meetings.","Presentation highlights onvansertib development pipeline and opportunity.","No financial results, guidance, or operational milestones disclosed.","Routine Regulation FD disclosure; no material changes to business."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102016,"accession_number":"0001193125-26-067476","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cardiff Oncology reports Phase 2 mCRC data: ORR 72.2% vs 43.2% SoC, PFS HR 0.37; plans registrational program","event_type":"other_material","confidence":"high","bullets":["Phase 2 CRDF-004: ORR 72.2% vs 43.2% combined SoC; PFS HR 0.37 (p<0.05) for 30 mg onvansertib + FOLFIRI/bev in first-line RAS-mutated mCRC.","Plans to advance 30 mg dose into registrational program; detailed data and FDA discussions expected H1 2026.","Cash $58.3M as of Dec 31, 2025; funds operations into Q1 2027. Total op ex $49.6M, slight increase from $49.3M in 2024.","Executive changes: Mani Mohindru appointed interim CEO; Brigitte Lindsay promoted to CAO; search for permanent CEO/CFO ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102015,"accession_number":"0001193125-26-024375","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2026-01-27T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Cardiff Oncology CEO and CFO step down; onvansertib Phase 2 hits 72.2% ORR in mCRC","event_type":"other_material","confidence":"high","bullets":["CEO Mark Erlander and CFO James Levine stepped down; Mani Mohindru named interim CEO, Brigitte Lindsay promoted to CAO.","Phase 2 CRDF-004: onvansertib 30mg + FOLFIRI/bev showed 72.2% ORR vs 43.2% SoC (p=0.051) and PFS HR 0.37 vs SoC (p=0.048).","Company selected 30mg dose of onvansertib with FOLFIRI/bev for registrational program; plans to initiate later in 2026 after FDA consultation.","Final data and registrational plans expected in H1 2026; onvansertib well-tolerated with no additive toxicity.","Conference call today at 8:30 a.m. ET to discuss results and strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118359,"accession_number":"0001193125-25-269492","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cardiff Oncology Q3 cash $60.6M; Phase 2 trial shows 19% ORR improvement in mCRC","event_type":"earnings","confidence":"high","bullets":["Onvansertib 30mg cohort showed 19% improvement in confirmed ORR vs control in RAS-mutated mCRC Phase 2 trial.","Cash and investments $60.6M as of Sep 30, 2025; projected runway into Q1 2027.","Net cash used in Q3 2025 was $10.8M, an increase of $0.3M from $10.5M in Q3 2024.","Total operating expenses for Q3 2025 were $12.1M, down from $12.8M in the same prior-year period.","Next clinical update from Phase 2 CRDF-004 trial expected in Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":350000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134796,"accession_number":"0000950170-25-099631","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Cardiff Oncology reports 49% confirmed ORR with onvansertib+SoC in Phase 2 mCRC trial; Q2 cash $71M","event_type":"other_material","confidence":"high","bullets":["Confirmed ORR 49% (30mg onvansertib+SoC) vs 30% control in ITT population (N=110); early PFS trend favoring 30mg.","Onvansertib well-tolerated; neutropenia most common grade 3+ AE; no unexpected toxicities.","Q2 operating expenses $14.9M (vs $12.7M); cash and investments $71.0M; runway into Q1 2027.","Appointed Dr. Roger Sidhu as CMO; completed enrollment in 41-site CRDF-004 trial.","Company expects to provide update on first-line mCRC program by Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151713,"accession_number":"0001641172-25-016659","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cardiff Oncology stockholders approve all proposals at 2025 annual meeting","event_type":"other","confidence":"high","bullets":["Seven director nominees elected, including CEO Mark Erlander, with between 20.4M and 21.2M votes each.","Ratification of BDO USA as independent auditor for FY2025: 36.3M for, 1.2M against.","Amendment to 2021 Equity Incentive Plan approved (16.9M for, 5.0M against); shares available increased to 12.15M.","Advisory say-on-pay vote on named executive officer compensation approved (18.9M for, 2.6M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151712,"accession_number":"0000950170-25-087369","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Cardiff Oncology appoints Dr. Roger Sidhu as CMO; to share CRDF-004 data on July 29","event_type":"leadership","confidence":"high","bullets":["Dr. Fairooz Kabbinavar stepped down as CMO effective June 13, 2025; will remain as advisor.","Dr. Roger Sidhu appointed CMO; previously at Amgen, Treadwell Therapeutics, Roivant Sciences.","Sidhu receives $515K base salary, 45% target bonus, and option for 600K shares at $3.86 vesting over 4 years.","Company to report additional clinical data from Phase 2 CRDF-004 trial in RAS-mutated mCRC on July 29, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}